Abstract

The aim of this study was to evaluate the effects of a dorzolamide-timolol fixed combination (DTFC) on intraocular pressure (IOP), heart rate (HR), blood pressure (BP), ocular perfusion pressure (OPP), and diastolic ocular perfusion pressure (DOPP) in patients with normal-tension glaucoma (NTG). A prospective, interventional, single-blind, single-center study was conducted. Newly diagnosed NTG patients that had not been treated with a glaucoma medication in the most recent 4weeks were included. Patients were examined at baseline (without medication) and week 4 (under medication). Baseline IOP, HR, systolic and diastolic BP, OPP, and DOPP were measured at 8am, 12pm, and 4pm. At week 4, IOP, HR, systolic and diastolic BP, OPP, and DOPP were measured at 10am and 8pm as well. After 4weeks of DTFC treatment, IOP was significantly reduced at all time points (1.6-2.6mmHg, P<0.001), and the average IOP reduction was 14.4%. HR and systolic BP showed no statistically significant difference at all time points; however, diastolic BP was decreased significantly at 12pm and 4pm (P=0.004 and 0.001). OPP and DOPP showed no statistical significant difference after DTFC. DTFC has favorable effects on IOP and can be used without concerns of DOPP in patients with NTG.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call